ClinicalTrials.gg
CompletedNCT00734604Updated Nov 18, 2010Results posted

A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.

A Phase 3 interventional study of tadalafil once a day [T(OaD)] and sildenafil citrate as needed [S(PRN)] in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 37 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
16th of 56
378 · median 199
Started
2008
the only one that year
Phase 3
19 of 57
2 open now
Registered
21st of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 16th largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2008, is one of 19 in phase 3, and was the 21st registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED).

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of erectile dysfunction (ED).
  • Have had satisfactory response to tadalafil, sildenafil citrate, or vardenafil HCl for a period of at least 6 months and expect frequent use (at least one dose per week, on average) when administered as needed.
  • Have never used tadalafil 5 mg or 2.5 mg once a day therapy.
  • Anticipate having the same adult female sexual partner willing to participate during the study.
  • Agree to make at least four sexual intercourse attempts during the first four weeks of the study.
  • Agree not to use any other treatment for ED (even herbal treatments) during the study.
  • Agree to follow the directions given by the study doctor and staff about using the study drug.

Exclusion criteria

Exclusion Criteria:

  • Have any other primary sexual disorders present or penile deformity.
  • Have history of radical prostatectomy or penile implant.
  • Have problems with your kidneys, liver, or nervous system.
  • Have uncontrolled diabetes, as measured by a blood test for greater than a value of 11%.
  • Are being treated for heart disease with any drug that is called a nitrate (for example, nitroglycerin).
  • Have chest pain (called unstable angina or angina) that requires treatment.
  • Have heart disease that causes symptoms after you exert yourself.
  • Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).
  • Have a history of loss of vision in one eye because of nonarteritic anterior ischemic optic neuropathy (NAION).
  • Have retinitis pigmentosa.
  • Have history of (HIV).
  • Have very high or very low blood pressure (your study doctor will discuss the limits with you).
  • Have had a stroke or a significant injury to your brain or spinal cord within the last 6 months.
  • Have rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption Lactose intolerance.
  • Have a scheduled or planned surgery requiring anaesthesia during the course of the study.
  • Have a scheduled cataract surgery during the curse of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
378 participants (actual)

Study arms

  • Experimental
    T(OaD)/S(PRN)/T(PRN)

    Tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks

    Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]

  • Experimental
    T(OaD)/T(PRN)/S(PRN)

    Tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks

    Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]

  • Experimental
    S(PRN)/T(OaD)/T(PRN)

    Sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks

    Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]

  • Experimental
    S(PRN)/T(PRN)/T(OaD)

    Sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks

    Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]

  • Experimental
    T(PRN)/T(OaD)/S(PRN)

    Tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks

    Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]

  • Experimental
    T(PRN)/S(PRN)/T(OaD)

    Tadalafil 20 mg as needed \[T(PRN)\] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed \[S(PRN)\] for 8 weeks, 1 week washout, tadalafil 5 mg once a day \[T(OaD)\] for 8 weeks

    Drug: tadalafil once a day [T(OaD)] · Drug: sildenafil citrate as needed [S(PRN)] · Drug: tadalafil as needed [T(PRN)]

Interventions

  • 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

    Also known as: Cialis, LY450190

  • Drugsildenafil citrate as needed [S(PRN)]

    100 mg tablet taken as needed (PRN) by mouth for 8 weeks

  • 20 mg tablet taken as needed (PRN) by mouth for 8 weeks

    Also known as: Cialis, LY450190

06

What researchers measure

Primary outcomes

  1. Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)

    The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.

    Time frame: baseline, 8 weeks of each treatment

Secondary outcomes

  1. Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)

    The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.

    Time frame: baseline, 8 weeks of each treatment

  2. Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS

    The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.

    Time frame: baseline, 8 weeks of each treatment

  3. Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS

    The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.

    Time frame: baseline, 8 weeks of each treatment

  4. Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)

    Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.

    Time frame: baseline, 8 weeks of each treatment

  5. Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection

    Time frame: baseline, 8 weeks of each treatment

  6. Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF

    Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.

    Time frame: baseline, 8 weeks of each treatment

  7. Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF

    Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.

    Time frame: baseline, 8 weeks of each treatment

  8. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint

    EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).

    Time frame: 8 weeks of each treatment

  9. Number of Participants With at Least One Serious Adverse Event

    Serious adverse events are listed in the Reported Adverse Event module.

    Time frame: baseline through 26 weeks (including two washout periods of 1 week each)

  10. Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score

    Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.

    Time frame: baseline, 8 weeks of each treatment

  11. Question 1 "I Felt as if I Did Not Have ED" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

    Scores for Question 1 range from 0 (not at all) to 4 (extremely).

    Time frame: 8 weeks of each treatment

  12. Question 2 "I Felt in Control of my Sex Life" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

    Scores for Question 2 range from 0 (not at all) to 4 (extremely).

    Time frame: 8 weeks of each treatment

  13. Question 3 "I Felt the Drug Was in Control of my Erections" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

    Scores for Question 3 range from 0 (not at all) to 4 (extremely).

    Time frame: 8 weeks of each treatment

  14. Question 4 "I Felt Like a Whole Man" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

    Scores for Question 4 range from 0 (not at all) to 4 (extremely).

    Time frame: 8 weeks of each treatment

07

Results

Posted Nov 18, 2010

Participant flow

Participant flow — Overall Study
MilestoneT(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)
Started626363636364
Completed595157545558
Not completed3126986
Withdrew: Adverse event020211
Withdrew: Serious adverse event101201
Withdrew: Lost to follow-up122423
Withdrew: Physician decision011000
Withdrew: Protocol violation020010
Withdrew: Sponsor decision121020
Withdrew: Withdrawal by subject020121
Withdrew: Lack of efficacy011000

Outcome measures

PrimaryChange From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)

The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline Between Tadalafil Once a Day (OaD) and Sildenafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]
Baseline2.24 ± 0.622.23 ± 0.63
Change from Baseline0.50 ± 0.780.39 ± 0.67
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = 0.001 (p-value is for difference in LS Means change from baseline between tadalafil OaD and Sildenafil PRN.) · Mean difference (final values): 0.12 · 95% CI 0.04 to 0.19Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryChange From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)

The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Sexual Self-Confidence score is the average of responses on 6 PAIRS item scores. Sexual Self-Confidence scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline Between Tadalafil Once a Day (OaD) and Tadalafil as Needed (PRN) in Sexual Self-Confidence Domain of Psychological and Interpersonal Relationship Scales (PAIRS)
units on a scaleTadalafil Once a Day [T(OaD)]Tadalafil as Needed [T(PRN)]
Baseline2.24 ± 0.622.24 ± 0.63
Change from Baseline0.50 ± 0.780.50 ± 0.72
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = 0.872 (p-value is for difference in Pairs Sexual Self-Confidence Domain Score LS Mean and Change from Baseline between Tadalafil OaD and Tadalafil PRN Population) · Mean difference (final values): 0.01 · 95% CI -0.06 to 0.08LS Mean difference = Tadalafil OaD-Tadalafil PRN
SecondaryChange From Baseline to Endpoint in the Spontaneity Domain of PAIRS

The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Spontaneity score is the average of responses on 9 PAIRS item scores. Spontaneity scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater spontaneity.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in the Spontaneity Domain of PAIRS
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Baseline3.06 ± 0.483.07 ± 0.483.07 ± 0.48
Change from Baseline0.10 ± 0.50-0.05 ± 0.490.07 ± 0.49
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = <0.001 (p-value is for difference between Tadalafil OaD and Sildenafil PRN change from baseline in LS Mean.) · Mean difference (final values): 0.15 · 95% CI 0.10 to 0.20Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = 0.395 (p-value is for difference between Tadalafil OaD and Tadalafil PRN in change from baseline in LS Mean.) · Mean difference (final values): 0.02 · 95% CI -0.03 to 0.07Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryChange From Baseline to Endpoint in the Time Concerns Domain of PAIRS

The PAIRS is a self-administed scale that assesses the broader psychological and interpersonal outcomes associated with erectile dysfunction and its treatment. Time Concerns score is the average of responses on 8 PAIRS item scores. Time Concerns scores range from 1 (strongly disagree) to 4 (strongly agree). Higher scores are indicative of greater sexual self-confidence.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in the Time Concerns Domain of PAIRS
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Baseline2.43 ± 0.532.42 ± 0.542.42 ± 0.53
Change from Baseline-0.30 ± 0.030.00 ± 0.53-0.17 ± 0.55
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = <0.001 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN in Change from Baseline in LS Mean.) · Mean difference (final values): -0.31 · 95% CI -0.36 to -0.25Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = <0.001 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN in Change from Baseline in LS Mean.) · Mean difference (final values): -0.14 · 95% CI -0.20 to -0.08Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryChange From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)

Self-reported erectile function over the past 4 weeks. Scores range from 0 (low or no erectile function) to 5 (high erectile function) on 6 questions (1-5, 15 of the IIEF). Total Erectile Function Domain scores range from 0 to 30.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in the Erectile Function Domain of the International Index of Erectile Function (IIEF)
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Baseline15.60 ± 6.2615.40 ± 6.2715.55 ± 6.23
Change from Baseline8.68 ± 6.949.70 ± 7.019.54 ± 7.00
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = 0.004 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -0.85 · 95% CI -1.43 to -0.27Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = 0.007 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -0.80 · 95% CI -1.37 to -0.22Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryChange From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection
Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · proportion of days
Change From Baseline to Endpoint in the Proportion of Days With at Least One Morning Erection
proportion of daysTadalafil Once a Day [T(OaD)]Tadalafil as Needed [T(PRN)]Sildenafil as Needed [S(PRN)]
Baseline0.28 ± 0.260.28 ± 0.260.27 ± 0.26
Change from Baseline0.26 ± 0.290.20 ± 0.250.11 ± 0.24
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = <0.001 (p-value is for difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.) · Mean difference (final values): 0.06 · 95% CI 0.03 to 0.09Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = <0.001 (p-value is for difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.) · Mean difference (final values): 0.09 · 95% CI 0.06 to 0.12Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryChange From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF

Self-reported intercourse satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 3 questions of the IIEF-IS domain range from 0 to 15.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in the Intercourse Satisfaction (IS) Domain of the IIEF
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Baseline8.35 ± 2.768.34 ± 2.778.37 ± 2.73
Change from Baseline3.33 ± 3.163.99 ± 3.173.83 ± 3.13
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = <0.001 (p-value is for difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -0.64 · 95% CI -0.91 to -0.36Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = <0.001 (p-value is for difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -0.51 · 95% CI -0.78 to -0.23
SecondaryChange From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF

Self-reported overall satisfaction over the past 4 weeks. Scores range from 0 (low/no satisfaction to 5 (high satisfaction), thus the 2 questions of the IIEF-OS domain range from 0 to 10.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in the Overall Satisfaction (OS) Domain of the IIEF
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Baseline5.26 ± 2.345.22 ± 2.365.27 ± 2.34
Change from Baseline2.60 ± 2.612.87 ± 2.552.84 ± 2.58
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = 0.055 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -0.22 · 95% CI -0.44 to 0.00Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = 0.046 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -0.22 · 95% CI -0.44 to 0.00Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryErectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint

EDITS is a questionnaire-based inventory capturing a participant's subjective evaluation of treatment for the participant's erection problems. All items on the 11-item Patient EDITS were scored from zero (no satisfaction or dissatisfaction) to four (high satisfaction). The EDITS Summary Score (transformed) is obtained by adding each individual score for all questions, dividing by the number of questions, and multiplying by 25, so that EDITS scores could range from a low of 0 (extremely low treatment satisfaction) to a high of 100 (extremely high treatment satisfaction).

Time frame:
8 weeks of each treatment
Reported as:
Mean · units on a scale
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Score at Endpoint75.81 ± 22.3675.68 ± 19.5879.50 ± 19.56
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = 0.004 (p-value is for the difference between Tadalafil PRN and Sildenafil PRN change in LS Means.) · Mean difference (final values): 3.66 · 95% CI 1.16 to 6.17Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = 0.006 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN change in LS Means.) · Mean difference (final values): -3.55 · 95% CI -6.05 to -1.04Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryNumber of Participants With at Least One Serious Adverse Event

Serious adverse events are listed in the Reported Adverse Event module.

Time frame:
baseline through 26 weeks (including two washout periods of 1 week each)
Reported as:
Number · participants
Number of Participants With at Least One Serious Adverse Event
participantsTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Number of Participants With at Least One Serious Adverse Event452
SecondaryChange From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score

Measures improvement in self-esteem and relationship satisfaction. Questionnaire consists of two domains, Sexual Relationship (items 1-8) and Confidence (items 9-14). Overall score is transformed onto a 0 (least favorable) to 100 (most favorable) scale. Overall score was calculated from two domains and subscales scores.

Time frame:
baseline, 8 weeks of each treatment
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in the Self-Esteem And Relationship (SEAR) Questionnaire Transformed Total Score
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Baseline50.28 ± 21.3650.50 ± 21.5850.69 ± 21.32
Change from Baseline22.94 ± 24.8622.87 ± 24.4324.13 ± 24.53
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · t-test · p = 0.915 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN Change from Baseline in LS Means.) · Mean difference (final values): 0.11 · 95% CI -1.95 to 2.17Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · t-test · p = 0.212 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN Change from Baseline in LS Means.) · Mean difference (final values): -1.30 · 95% CI -3.35 to 0.74Kenward-Roger approximation was used for denominator degrees of freedom in the mixed model.
SecondaryQuestion 1 "I Felt as if I Did Not Have ED" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

Scores for Question 1 range from 0 (not at all) to 4 (extremely).

Time frame:
8 weeks of each treatment
Reported as:
Mean · units on a scale
Question 1 "I Felt as if I Did Not Have ED" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Question 1 "I Felt as if I Did Not Have ED" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint1.83 ± 1.251.78 ± 1.131.77 ± 1.22
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · Generalized Linear Mixed Model · p = 0.403 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.) · Mean difference (final values): 0.07 · 95% CI -0.09 to 0.22
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · Generalized Linear Mixed Model · p = 0.367 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.) · Mean difference (final values): 0.07 · 95% CI -0.08 to 0.23
SecondaryQuestion 2 "I Felt in Control of my Sex Life" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

Scores for Question 2 range from 0 (not at all) to 4 (extremely).

Time frame:
8 weeks of each treatment
Reported as:
Mean · units on a scale
Question 2 "I Felt in Control of my Sex Life" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Question 2 "I Felt in Control of my Sex Life" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint2.33 ± 1.092.14 ± 1.012.36 ± 1.10
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · Generalized Linear Mixed Model · p = 0.002 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.) · Mean difference (final values): 0.20 · 95% CI 0.07 to 0.32
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · Generalized Linear Mixed Model · p = 0.722 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.) · Mean difference (final values): -0.02 · 95% CI -0.15 to 0.10
SecondaryQuestion 3 "I Felt the Drug Was in Control of my Erections" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

Scores for Question 3 range from 0 (not at all) to 4 (extremely).

Time frame:
8 weeks of each treatment
Reported as:
Mean · units on a scale
Question 3 "I Felt the Drug Was in Control of my Erections" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Question 3 "I Felt the Drug Was in Control of my Erections" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint1.99 ± 1.192.28 ± 1.122.50 ± 1.14
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · Generalized Linear Mixed Model · p = <0.001 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.) · Mean difference (final values): -0.51 · 95% CI -0.65 to -0.37
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · Generalized Linear Mixed Model · p = <0.001 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.) · Mean difference (final values): -0.29 · 95% CI -0.43 to -0.16
SecondaryQuestion 4 "I Felt Like a Whole Man" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint

Scores for Question 4 range from 0 (not at all) to 4 (extremely).

Time frame:
8 weeks of each treatment
Reported as:
Mean · units on a scale
Question 4 "I Felt Like a Whole Man" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint
units on a scaleTadalafil Once a Day [T(OaD)]Sildenafil as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
Question 4 "I Felt Like a Whole Man" Score of the Patient Perception and Feelings Questions (PPF-Q) at Endpoint2.53 ± 1.102.57 ± 1.062.44 ± 0.99
Statistical analysis
  • Tadalafil Once a Day [T(OaD)] vs Sildenafil as Needed [S(PRN)] · Generalized Linear Mixed Model · p = 0.070 (p-value is for the difference between Tadalafil OaD and Sildenafil PRN in LS Means.) · Mean difference (final values): 0.11 · 95% CI -0.01 to 0.22
  • Tadalafil Once a Day [T(OaD)] vs Tadalafil as Needed [T(PRN)] · Generalized Linear Mixed Model · p = 0.637 (p-value is for the difference between Tadalafil OaD and Tadalafil PRN in LS Means.) · Mean difference (final values): -0.03 · 95% CI -0.14 to 0.09

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil Once a Day [T(OaD)]—4/378 (1.1%)66/378 (17.5%)
Sildenafil Citrate as Needed [S(PRN)]—5/378 (1.3%)73/378 (19.3%)
Tadalafil as Needed [T(PRN)]—2/378 (0.5%)70/378 (18.5%)
Most frequent serious events
Most frequent serious events
EventTadalafil Once a Day [T(OaD)]Sildenafil Citrate as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
PneumoniaInfections and infestations2/3781/3780/378
Coronary artery occlusionCardiac disorders0/3781/3780/378
Myocardial infarctionCardiac disorders0/3780/3781/378
Retinal detachmentEye disorders1/3780/3780/378
FallInjury, poisoning and procedural complications1/3780/3780/378
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3781/3780/378
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3781/3780/378
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3780/3781/378
Elbow operationSurgical and medical procedures0/3781/3780/378
Most frequent other events
Showing 10 of 99
Most frequent other events
EventTadalafil Once a Day [T(OaD)]Sildenafil Citrate as Needed [S(PRN)]Tadalafil as Needed [T(PRN)]
HeadacheNervous system disorders10/37813/3788/378
Nasal congestionRespiratory, thoracic and mediastinal disorders5/3788/3783/378
FlushingVascular disorders6/3788/3783/378
DyspepsiaGastrointestinal disorders6/3785/3784/378
Back painMusculoskeletal and connective tissue disorders3/3783/3785/378
MyalgiaMusculoskeletal and connective tissue disorders5/3780/3781/378
DiarrhoeaGastrointestinal disorders3/3784/3782/378
HypertensionVascular disorders2/3782/3784/378
Gastrooesophageal reflux diseaseGastrointestinal disorders3/3783/3782/378
Lower respiratory tract infectionInfections and infestations2/3783/3782/378

Baseline characteristics

Age Continuous
Age Continuous(years)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
Mean58.53 ± 11.6255.12 ± 8.8955.40 ± 11.7054.87 ± 12.0459.04 ± 10.5654.36 ± 10.2856.21 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
Female0000000
Male626363636364378
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
African11143212
Caucasian414446414340255
East Asian1010013
Hispanic191715181719105
Native American0000022
West Asian0100001
Region of Enrollment
Region of Enrollment(participants)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
Australia34544424
Germany76677740
Italy55464529
Mexico14141414141484
Spain10101099957
United Kingdom68778844
United States171617161717100
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
Mean28.35 ± 4.1827.62 ± 2.6527.77 ± 3.7128.68 ± 4.7427.80 ± 3.5129.08 ± 4.2628.22 ± 3.91
Erectile Dysfunction (ED) Duration
Erectile Dysfunction (ED) Duration(participants)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
=> 1 year596158586159356
=> than 6 months through <1 year32552522
ED Etiology
ED Etiology(participants)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
Mixed252621232328146
Organic222829293025163
Psychogenic53991734
Unknown106429435
Prior sildenafil citrate use as needed (PRN)
Prior sildenafil citrate use as needed (PRN)(participants)T(OaD)/S(PRN)/T(PRN)T(OaD)/T(PRN)/S(PRN)S(PRN)/T(OaD)/T(PRN)S(PRN)/T(PRN)/T(OaD)T(PRN)/T(OaD)/S(PRN)T(PRN)/S(PRN)/T(OaD)Total
Yes364040393935229
No262323242429149

1 further baseline measures are reported on the registry.

08

Study locations

37 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huntsville, Alabama 35801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newport Beach, California 92660, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Middlebury, Connecticut 06762, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plantation, Florida 33317, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37920, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Federal Way, Washington 98003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adelaide, South Australia 5000, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malvern, Victoria 3144, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nedlands, Western Australia 6009, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goiânia, 74110-020, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio Claro, 13500-020, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio De Janeiro, 20725-090, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Jose Rio Preto, 15090-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Paulo, 04044-060, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augsburg, 86150, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13465, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milan, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sassari, 07100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torino, 10126, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Joya, 14000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 10700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64040, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00912, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santurce, 00907, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08025, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Coruña, 15006, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malaga, 29007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vigo, 36211, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, County Durham DH1 2QW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plymouth, Devonshire PL6 8BX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lichfield, Staffordshire WS14 9JL, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, NW8 9NH, United Kingdom
09

References and documents

Publications

  • Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G, Morales AM, Stuckey B, Buttner H, West TM, Huynh NN, Lenero E, Burns P, Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012 May;9(5):1418-29. doi: 10.1111/j.1743-6109.2012.02667.x. Epub 2012 Mar 16. PubMed 22429760 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2008
First posted
Aug 14, 2008
Start
Aug 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Nov 18, 2010
Last update
Nov 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00734604
First posted
Aug 14, 2008
Start date
Aug 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Nov 18, 2010
Last update
Nov 18, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Easter Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion